Carlsson Sigrid, Vickers Andrew
BMC Med. 2015 Mar 24;13:60. doi: 10.1186/s12916-015-0311-x.
Recent decades have seen dramatic changes in the management of prostate cancer based on novel research findings. Prostate-specific antigen (PSA) screening has been introduced, and then recently modified to include new strategies and biomarkers. Management of advanced disease has been transformed by the rapid introduction of new agents. We have moved from a "one-size-fits-all" approach in prostate cancer management to multidisciplinary strategies tailored to the individual patient and his specific cancer. This editorial marks the launch of the article collection Spotlight on prostate cancer (http://www.biomedcentral.com/bmcmed/series/SPR), and here, guest editors Sigrid Carlsson and Andrew Vickers give an overview of the past, present, and future of prostate cancer research and management.
近几十年来，基于新的研究发现，前列腺癌的管理发生了巨大变化。前列腺特异性抗原（PSA）筛查已经引入，并且最近进行了改进，纳入了新的策略和生物标志物。新药物的迅速推出改变了晚期疾病的管理方式。我们已经从前列腺癌管理的“一刀切”方法转向了针对个体患者及其特定癌症的多学科策略。这篇社论标志着文章合集《聚焦前列腺癌》（http://www.biomedcentral.com/bmcmed/series/SPR）的推出，在此，客座编辑西格丽德·卡尔松和安德鲁·维克斯对前列腺癌研究与管理的过去、现在和未来进行了概述。
